Citigroup Inc Aldeyra Therapeutics, Inc. Transaction History

Citigroup Inc

$150 Billion
Q1 2024

A detailed history of Citigroup Inc transactions in Aldeyra Therapeutics, Inc. stock. As of the latest transaction made, Citigroup Inc holds 7,802 shares of ALDX stock, worth $25,824. This represents 0.0% of its overall portfolio holdings.

Number of Shares

7,802

Previous 6,426 21.41%

Holding current value

$25,824

Previous $22,000 13.64%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	BUY	$2.77 - $4.22 $3,811 - $5,806	1,376 Added 21.41%	7,802 $25,000
Q4 2023 Feb 09, 2024	SELL	$1.47 - $6.06 $156,716 - $646,056	-106,610 Reduced 94.32%	6,426 $22,000
Q3 2023 Nov 09, 2023	BUY	$6.11 - $8.16 $177,379 - $236,892	29,031 Added 34.56%	113,036 $755,000
Q2 2023 Aug 10, 2023	BUY	$7.11 - $11.89 $251,829 - $421,131	35,419 Added 72.9%	84,005 $704,000
Q1 2023 May 11, 2023	BUY	$5.77 - $9.93 $21,729 - $37,396	3,766 Added 8.4%	48,586 $482,000

Q4 2022 Feb 09, 2023	BUY	$5.08 - $7.09 $202,224 - $282,238	39,808 Added 794.25%	44,820 $311,000
Q3 2022 Nov 10, 2022	SELL	$3.8 - $7.74 $1.37 Million - $2.8 Million	-361,218 Reduced 98.63%	5,012 $27,000
Q2 2022 Aug 10, 2022	BUY	$2.43 - $4.85 $885,698 - $1.77 Million	364,485 Added 20887.39%	366,230 $1.46 Million
Q1 2022 May 12, 2022	SELL	$3.25 - $5.17 $556,780 - $885,708	-171,317 Reduced 98.99%	1,745 $8,000
Q4 2021 Feb 10, 2022	BUY	$3.5 - $9.63 $272,706 - $750,331	77,916 Added 81.89%	173,062 $692,000
Q3 2021 Nov 10, 2021	BUY	$7.94 - $11.31 $755,459 - $1.08 Million	95,146 New	95,146 $835,000

Others Institutions Holding ALDX

# of Institutions

106

Shares Held

35.4M

Call Options Held

104K

Put Options Held

88.1K

View Full List

About Aldeyra Therapeutics, Inc.

Ticker ALDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,323,100
Market Cap $193M
Description
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It al...

More about ALDX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Account